Skip to main contentSkip to navigationSkip to search

Lipum and NorthX Biologics enter into new strategic
manufacturing alliance

Lipum AB (Publ), a clinical stage biopharmaceutical company specialized in discovery and
development of a novel treatment for chronic inflammatory diseases today announces that
it has entered into a manufacturing alliance with NorthX Biologics AB, a Contract
Development and Manufacturing Organisation (CDMO).

Under this agreement NorthX will manufacture Lipum´s lead asset, SOL-116, a humanized antibody,
for use in a phase II clinical trial. SOL-116 is transferred from the current manufacturer to NorthX
which will lead to cost and time savings with high quality.

Ola Sandborgh, CEO of Lipum said “We are delighted to be partnering with NorthX and it represents an
important step as we move forward into our phase II trial. NorthX´s capabilities are a great fit and provide
a cost effective one-stop-shop for both drug substance and sterile fill finish drug product. I am very much
looking forward to the collaboration and bringing this therapy a step closer to patients”.
Janet Hoogstraate, CEO of NorthX Biologics added “We are excited to be working on SOL-116 and look
forward to adding our expertise and experience in the GMP manufacture of advanced biologics to the
ultimate benefit of patients”.

About NorthX Biologics AB
NorthX Biologics, a leading Nordic Development and Manufacturing Organization, has expertise in
producing cell and gene therapies, proteins, vaccines, other advanced biologics. With two sites in
Sweden and headquartered in Matfors, the team has been manufacturing biologics to GMP standards
since 1992. In 2021 NorthX was designated a national innovation hub for advanced therapies and
vaccines and has the ambition to become a leading cell and gene therapy manufacturer and partner
for innovative drug development companies. For more information see

Press Release Download here.

Ola Sandborgh, CEO
+46 72 218 80 21